Integrated Report
Integrated Report 2022 (For the year ended March 31, 2022)
Full Report
By Section
- Profile
- From Sumitomo Dainippon Pharma to Sumitomo Pharma(PDF/1,664KB)
- History of Value Creation and Growth(PDF/551KB)
- Corporate Mission / Corporate Culture(PDF/430KB)
- Main Products(PDF/549KB)
- Financial Highlights(PDF/480KB)
- Non-Financial Highlights(PDF/464KB)
- Table of Contents / Editorial Policy(PDF/541KB)
- Value Creation Strategies
- Changes in the Environment Surrounding Pharmaceutical Companies(PDF/561KB)
- Opportunities and Risks(PDF/420KB)
- Business Model(PDF/713KB)
- Message from the President(PDF/1,017KB)
- Financial Policy (Message from the President)(PDF/546KB)
- Information Disclosure Based on the TCFD Recommendations (Responses to Climate Change)(PDF/429KB)
- Feature: Fostering "CHANTO," the capability to deliver the highest performance(PDF/664KB)
- Sustainability and Materiality(PDF/490KB)
- Mid-term Business Plan(PDF/425KB)
- Practice & Performance
- Mid-term Business Plan 2022(PDF/418KB)
- Basic Policy I
Establishment of growth engine(PDF/5,284KB) - Strategy 1 Enhance innovation base with new approaches to drug discovery
- Strategy 2 Deliver the highest performance of clinical development
- Message from the Executive Officers
- Strategy 3 Pipeline expansion through strategic investment
- Strategy 4 Regional strategy centering in Japan, North America and China
- Strategy 5 Launch frontier business
-
Basic Policy II
Building of flexible and efficient organization(PDF/2,873KB) - Flexible and efficient organization and operations
- Corporate culture and talent to drive innovation
- Message from the Executive Officer in Charge of Human Resources
- Digital transformation
- Environment(PDF/708KB)
- Contribution to Societies(PDF/871KB)
- Governance
- Corporate Governance(PDF/2,067KB)
- Financial & Corporate Information
- Ten-Year Summary of Selected Financial Data(PDF/431KB)
- Operating Results and Financial Condition, and Business Risks(PDF/457KB)
- Consolidated Financial Statements(PDF/444KB)
- Value Chain Initiatives(PDF/716KB)
- Basic Knowledge of Pharmaceuticals(PDF/426KB)
- Corporate Profile / Shareholder Data(PDF/424KB)
- External Evaluations(PDF/518KB)
Integrated Report 2021 (For the year ended March 31, 2021)
English (178 pages)Full Report (PDF/11,899KB)
Integrated Report 2020 (For the year ended March 31, 2020)
English (158 pages)Full Report (PDF/6654KB)
Integrated Report 2019 (For the year ended March 31, 2019)
English (130 pages)Full Report (PDF/5070KB)
Integrated Report 2018 (For the year ended March 31, 2018)
English (138 pages)Full Report (PDF/8011KB)
Annual Report 2017 (For the year ended March 31, 2017)
English (102 pages)Full Report (PDF/7691KB)
Annual Report 2016(For the year ended March 31, 2016)
English (96 pages)Full Report (PDF/6048KB)
Annual Report 2015(For the year ended March 31, 2015)
English (90 pages)Full Report (PDF/3047KB)
Annual Report 2014(For the year ended March 31, 2014)
English (92 pages)Full Report (PDF/8946KB)
Annual Report 2013(For the year ended March 31, 2013)
English (89 pages)Full Report (PDF/4995KB)
Annual Report 2012(For the year ended March 31, 2012)
English (81 pages)Full Report (PDF/9358 KB)
Annual Report 2011(For the year ended March 31, 2011)
English (75 pages)Full Report (PDF/3191KB)
Annual Report 2010(For the year ended March 31, 2010)
English (79 pages)Full Report (PDF/4232KB)
Annual Report 2009(For the year ended March 31, 2009)
English (53 pages)Full Report (PDF/1068KB)
Annual Report 2008(For the year ended March 31, 2008)
English (55 pages)Full Report (PDF/1944KB)
Annual Report 2007(For the year ended March 31, 2007)
English (53 pages)Full Report (PDF/1020KB)
Annual Report 2006(For the year ended March 31, 2006)
English (53 pages)Full Report (PDF/1168KB)